Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3, 12-Month Open-Label Study of Lasmiditan in Pediatric Migraine
2019-004379-38Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lasmiditan in migraine, sponsored by Eli Lilly and Company. Primary endpoint: Treatment-Emergent Adverse Events by treated attack. Started Jun 2020; status: active.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on 2019-004379-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004379-38.